Business Context and Reporting Period
This Form 8-K is a current report filed by Hemispherx Biopharma, Inc. on December 6, 2013, covering events occurring on December 2 and December 3, 2013. The filing addresses significant changes in corporate governance and management personnel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial statements or performance data.
Material Changes
- Appointment of CFO: On December 2, 2013, Thomas K. Equels was appointed Chief Financial Officer. He previously served as Executive Vice Chairman, Secretary, and General Counsel.
- Transition Plan: Mr. Equels will work with outgoing CFO Charles T. Bernhardt until Mr. Bernhardt's departure on December 27, 2013.
- Appointment of CAO: On December 3, 2013, Adam Pascale was appointed Chief Accounting Officer. He had served as the Company's Controller for 18 years.
Management Commentary and Background
Management highlights Mr. Equels' extensive background in complex business litigation, corporate finance, and international matters, including a notable $26.8 million judgment against Bear Stearns in 2008. He also holds significant military honors from the Vietnam War. Mr. Pascale brings 24 years of public accounting experience and a CPA designation to the new role.
Investor Verification Checklist
- Verify the effective date of Charles T. Bernhardt's departure (December 27, 2013).
- Confirm the press release referenced as Exhibit 99.1 for additional context on the leadership changes.
- Review subsequent filings for the first financial report prepared under the new CFO leadership.